Prompt diagnosis of brain problemsincreases the effectiveness of the treatment of many diseases. Experts from Yale Hospital New Haven in New York conducted the second phase of testing of the bedside mobile MRI device POC MRI. The tests were carried out in an intensive care unit in the area where patients infected with COVID-19 with neuralgic disorders were treated.
The portable MRI device has detectedspecific brain abnormalities in 29 of 30 patients admitted to the neuroscience unit at Yale Hospital New Haven with symptoms of stroke and other neurological disorders. It is noted that the delivery of the MRI device to the patient's bed becomes as easy as the delivery of an ordinary wheelchair.
The study is the first attempt to expandmobile bedside device for magnetic resonance imaging of the brain. As a result, doctors will be provided with operational information that allows immediate diagnosis in almost any conditions. The use of a magnetic field with a strength of 0.064 T in the POC MRI installation (in stationary installations, fields with a strength of 1.5-3 T are used) can reduce energy consumption by 35 times and use a standard household outlet to connect the device. The weight and dimensions of the device are also reduced by almost 10 times in comparison with the stationary analogue.
Low power and small size of mobile MRIwill allow using the installation in ambulances for operational diagnostics. A more detailed examination of the patient will be carried out using full-fledged stationary devices in hospitals. Thus, mini MRI is not a competitor to the traditional technique, but complements it, allowing the detection of symptoms at an early stage right at the patient's bedside.
Installation cost is 20 times less than stationary. Transportation of MRI POC MRI does not pose a threat to others and it can be freely transported along the corridors of hospitals from ward to ward. In testing, which was completed recently, the installation was taken to the ward to patients diagnosed with COVID-19 infection.
Data obtained during testing at presentthe time is compared with the values obtained from stationary MRI machines. Based on this analysis, instructions for the use of the POC MRI will be developed, and the accuracy and uncertainty of the analysis in the field will be indicated. The developer company Hyperfine has received FDA approval for its prototype device. In the near future, the unit will be put into serial production.